Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced solid tumors. Oral dose escalation was investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneeweiss, Andreas, Hess, Dagmar, Joerger, Markus, Varga, Andrea, Moulder, Stacy, Tsimberidou, Apostolia M., Ma, Cynthia, Hurvitz, Sara A., Rentzsch, Christine, Rudolph, Marion, Thiele, Silke, Boix, Oliver, Wilkinson, Gary, Lagkadinou, Eleni, Ocker, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966663/
https://www.ncbi.nlm.nih.gov/pubmed/31835495
http://dx.doi.org/10.3390/cancers11121987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966663/
https://www.ncbi.nlm.nih.gov/pubmed/31835495
http://dx.doi.org/10.3390/cancers11121987

Ejemplares similares